Dr Sanjay Popat is a Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Reader in Cancer Medicine at Imperial College.
Sanjay qualified from Guy’s and St Thomas’ Hospitals in 1994 with triple distinction, the Solly Prize and Medal, and a First Class BSc in Experimental Pathology. He was awarded a PhD in Molecular Genetics in 2002 and thereafter undertook a post doctoral Clinician Scientist Fellowship, and subsequently a HEFCE Clinical Senior Lectureship. He has published in the fields of molecular genetics, therapeutic biomarkers, and medical oncology. He has been awarded nationally and internationally competitive prizes for his research, in addition to 4 research fellowships.
He is an internationally recognized expert in the treatment of lung cancer, mesothelioma and thymoma. His research interests include identification and validation of biomarkers that influence thoracic tumour development and treatment, as well as the development of novel therapeutic strategies for the treatment of thoracic tumours through clinical trials.
He Chairs the British Thoracic Oncology Group (BTOG), and is immediate past Chair of the Advanced Diseases Sub-group of the UK NCRI Lung Cancer Clinical Studies Group. He has been elected onto the Foundation Council of the European Thoracic Oncology Platform (ETOP), and is active in the European Organization for Research and Treatment of Cancer (EORTC) Lung Group- where he leads the EORTC 08114 (GEM) and 08112 (NEMO) studies- and the International Thymic Malignancy Interest Group (ITMIG).
et al., 2024, Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade., Cancers (basel), Vol:16, ISSN:2072-6694
et al., 2024, Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer., N Engl J Med, Vol:390, Pages:118-131
et al., 2024, Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers., J Comp Eff Res
et al., 2024, SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer., Ann Oncol, Vol:35, Pages:66-76
et al., 2024, TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection., Clin Lung Cancer, Vol:25, Pages:80-84